 Kevin Lillehei
Concepts (613)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pituitary Neoplasms | 29 | 2025 | 190 | 3.500 |
Why?
| | Adenoma | 23 | 2025 | 218 | 3.090 |
Why?
| | Brain Neoplasms | 48 | 2023 | 1331 | 2.860 |
Why?
| | Neurosurgical Procedures | 11 | 2025 | 202 | 1.980 |
Why?
| | Meningioma | 12 | 2022 | 88 | 1.900 |
Why?
| | Pituitary Gland | 11 | 2020 | 149 | 1.660 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 13 | 1.550 |
Why?
| | Glioblastoma | 18 | 2023 | 354 | 1.530 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 1150 | 1.290 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 95 | 1.270 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 19 | 1.050 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 177 | 0.890 |
Why?
| | Glioma | 15 | 2020 | 429 | 0.860 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.820 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 142 | 0.820 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.810 |
Why?
| | Cysts | 3 | 2020 | 112 | 0.730 |
Why?
| | Carmustine | 3 | 2017 | 52 | 0.690 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 740 | 0.680 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 12 | 0.670 |
Why?
| | Cancer Vaccines | 5 | 2018 | 162 | 0.660 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 100 | 0.650 |
Why?
| | Hypopituitarism | 1 | 2020 | 16 | 0.630 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 102 | 0.610 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 222 | 0.570 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2019 | 140 | 0.560 |
Why?
| | Polyesters | 2 | 2017 | 76 | 0.540 |
Why?
| | Decanoic Acids | 1 | 2017 | 12 | 0.530 |
Why?
| | Bleomycin | 1 | 2019 | 255 | 0.530 |
Why?
| | Immunotherapy | 4 | 2006 | 667 | 0.520 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3915 | 0.500 |
Why?
| | Adult | 72 | 2025 | 40872 | 0.490 |
Why?
| | Orbital Diseases | 1 | 2016 | 37 | 0.480 |
Why?
| | Middle Aged | 73 | 2025 | 36302 | 0.480 |
Why?
| | Aged | 54 | 2025 | 26215 | 0.440 |
Why?
| | Humans | 126 | 2025 | 145763 | 0.420 |
Why?
| | Male | 86 | 2025 | 73003 | 0.400 |
Why?
| | Brachial Plexus | 3 | 2007 | 34 | 0.380 |
Why?
| | Female | 83 | 2025 | 79035 | 0.380 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 2219 | 0.370 |
Why?
| | Retrospective Studies | 28 | 2025 | 17325 | 0.360 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1329 | 0.350 |
Why?
| | Dacarbazine | 7 | 2015 | 100 | 0.350 |
Why?
| | Skull Neoplasms | 4 | 2012 | 21 | 0.350 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 239 | 0.350 |
Why?
| | Craniopharyngioma | 3 | 2020 | 77 | 0.340 |
Why?
| | Cisplatin | 3 | 1998 | 345 | 0.340 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 342 | 0.330 |
Why?
| | Cautery | 1 | 2010 | 4 | 0.320 |
Why?
| | Extracellular Vesicles | 2 | 2024 | 171 | 0.320 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 74 | 0.320 |
Why?
| | Sella Turcica | 5 | 2018 | 17 | 0.310 |
Why?
| | Monosomy | 1 | 2010 | 10 | 0.310 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 2 | 2024 | 12 | 0.310 |
Why?
| | Epithelioid Cells | 1 | 2010 | 9 | 0.310 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 48 | 0.310 |
Why?
| | Neurosurgery | 2 | 2021 | 41 | 0.310 |
Why?
| | Astrocytoma | 5 | 2014 | 130 | 0.310 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1270 | 0.300 |
Why?
| | Hemangioma | 1 | 2009 | 46 | 0.290 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 130 | 0.290 |
Why?
| | Cadherins | 2 | 2024 | 200 | 0.290 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 328 | 0.280 |
Why?
| | Membrane Proteins | 2 | 2017 | 1166 | 0.270 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 103 | 0.270 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 29 | 0.260 |
Why?
| | Tumor Cells, Cultured | 8 | 2017 | 887 | 0.260 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 410 | 0.260 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.260 |
Why?
| | Young Adult | 16 | 2025 | 14251 | 0.260 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1723 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 1450 | 0.250 |
Why?
| | Prolactinoma | 3 | 2019 | 13 | 0.250 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 33 | 0.240 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 18 | 0.240 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1512 | 0.240 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 12 | 0.230 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 120 | 0.230 |
Why?
| | Gonadotrophs | 5 | 2015 | 21 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 72 | 0.230 |
Why?
| | Ethanol | 1 | 2010 | 631 | 0.230 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 268 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 751 | 0.220 |
Why?
| | Interleukin-2 | 6 | 1997 | 440 | 0.220 |
Why?
| | Chordoma | 1 | 2024 | 17 | 0.210 |
Why?
| | Hemangioblastoma | 1 | 2004 | 3 | 0.210 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1482 | 0.210 |
Why?
| | Neoplasms | 5 | 2013 | 2913 | 0.210 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 102 | 0.200 |
Why?
| | Treatment Outcome | 12 | 2020 | 11793 | 0.200 |
Why?
| | Osteoblasts | 1 | 2024 | 145 | 0.200 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 147 | 0.200 |
Why?
| | Adolescent | 20 | 2020 | 22573 | 0.200 |
Why?
| | Cell Movement | 2 | 2024 | 961 | 0.200 |
Why?
| | Neurologic Examination | 3 | 2019 | 132 | 0.200 |
Why?
| | Cauda Equina | 2 | 2004 | 6 | 0.200 |
Why?
| | Transcription Factors | 2 | 2010 | 1736 | 0.190 |
Why?
| | Postoperative Complications | 8 | 2018 | 2977 | 0.190 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 7 | 0.190 |
Why?
| | Drug Implants | 3 | 2017 | 83 | 0.190 |
Why?
| | Postoperative Period | 3 | 2020 | 351 | 0.190 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 220 | 0.190 |
Why?
| | Motor Cortex | 1 | 2003 | 65 | 0.180 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 119 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 534 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 177 | 0.180 |
Why?
| | Pituitary Diseases | 3 | 2017 | 20 | 0.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1969 | 0.170 |
Why?
| | Pineal Gland | 1 | 2021 | 15 | 0.170 |
Why?
| | Pinealoma | 1 | 2021 | 10 | 0.170 |
Why?
| | Aspergillus | 2 | 2013 | 18 | 0.170 |
Why?
| | Fistula | 1 | 2022 | 49 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 224 | 0.170 |
Why?
| | Frontal Bone | 2 | 2015 | 19 | 0.170 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 58 | 0.170 |
Why?
| | Prognosis | 10 | 2021 | 4329 | 0.170 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 928 | 0.170 |
Why?
| | Neuropathology | 1 | 2020 | 3 | 0.160 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 118 | 0.160 |
Why?
| | Telepathology | 1 | 2020 | 4 | 0.160 |
Why?
| | Follow-Up Studies | 8 | 2017 | 5428 | 0.160 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 65 | 0.160 |
Why?
| | Prospective Studies | 11 | 2023 | 8075 | 0.160 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.160 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 2 | 0.160 |
Why?
| | Fluorescein | 1 | 2020 | 24 | 0.160 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 611 | 0.160 |
Why?
| | Salivary Glands | 1 | 2020 | 36 | 0.160 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 42 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 735 | 0.160 |
Why?
| | Nose Neoplasms | 1 | 2000 | 22 | 0.150 |
Why?
| | Survival Analysis | 7 | 2018 | 1378 | 0.150 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 29 | 0.150 |
Why?
| | Transcriptome | 3 | 2024 | 1042 | 0.150 |
Why?
| | Radiosurgery | 3 | 2010 | 399 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2770 | 0.150 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 85 | 0.150 |
Why?
| | Neoplasm Grading | 2 | 2017 | 311 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 4 | 0.140 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2667 | 0.140 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 13 | 0.140 |
Why?
| | Polyethylenes | 1 | 2018 | 12 | 0.140 |
Why?
| | Dendritic Cells | 2 | 2023 | 500 | 0.140 |
Why?
| | Oligodendroglioma | 2 | 2014 | 15 | 0.140 |
Why?
| | International Educational Exchange | 1 | 2018 | 10 | 0.140 |
Why?
| | Endocrine Glands | 1 | 1998 | 14 | 0.140 |
Why?
| | ErbB Receptors | 4 | 2006 | 635 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 427 | 0.140 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 7 | 0.140 |
Why?
| | Antioxidants | 2 | 2000 | 550 | 0.140 |
Why?
| | Aged, 80 and over | 12 | 2020 | 8346 | 0.140 |
Why?
| | Survival Rate | 6 | 2015 | 2094 | 0.140 |
Why?
| | Stroke | 2 | 2021 | 1271 | 0.140 |
Why?
| | Time Factors | 10 | 2011 | 7133 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.130 |
Why?
| | Remission Induction | 1 | 2018 | 306 | 0.130 |
Why?
| | Adenocarcinoma | 2 | 2004 | 926 | 0.130 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 105 | 0.130 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 30 | 0.130 |
Why?
| | Mutation | 3 | 2014 | 4090 | 0.130 |
Why?
| | Quinazolines | 2 | 2010 | 266 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2018 | 137 | 0.130 |
Why?
| | Rats | 8 | 2006 | 5585 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1777 | 0.130 |
Why?
| | Thalamic Diseases | 1 | 2017 | 3 | 0.130 |
Why?
| | Xanthomatosis | 1 | 2017 | 8 | 0.130 |
Why?
| | Desmosomes | 1 | 2017 | 22 | 0.130 |
Why?
| | Third Ventricle | 1 | 2017 | 16 | 0.130 |
Why?
| | Exophthalmos | 1 | 2016 | 18 | 0.120 |
Why?
| | Reoperation | 5 | 2020 | 637 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 378 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2015 | 2514 | 0.120 |
Why?
| | Cytokines | 2 | 2021 | 2069 | 0.120 |
Why?
| | Progesterone | 1 | 2017 | 215 | 0.120 |
Why?
| | Brain Injuries | 1 | 2021 | 507 | 0.120 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 271 | 0.120 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.110 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.110 |
Why?
| | Tibial Nerve | 1 | 1995 | 9 | 0.110 |
Why?
| | Occipital Lobe | 2 | 2006 | 26 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 64 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1191 | 0.110 |
Why?
| | Glycoproteins | 3 | 2012 | 354 | 0.110 |
Why?
| | Genes, p53 | 2 | 2011 | 67 | 0.110 |
Why?
| | Olfactory Pathways | 1 | 2015 | 38 | 0.110 |
Why?
| | Accidents, Aviation | 1 | 1994 | 5 | 0.110 |
Why?
| | Karyotyping | 3 | 2008 | 106 | 0.110 |
Why?
| | Proteome | 2 | 2024 | 513 | 0.110 |
Why?
| | Orbit | 1 | 2015 | 66 | 0.110 |
Why?
| | Molecular Chaperones | 2 | 2013 | 199 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 429 | 0.110 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 508 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 17 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 1995 | 85 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 41 | 0.100 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 41 | 0.100 |
Why?
| | Ganglioglioma | 1 | 2014 | 34 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2014 | 47 | 0.100 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 28 | 0.100 |
Why?
| | Ganglioneuroma | 1 | 2013 | 1 | 0.100 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 3 | 0.100 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 6 | 0.100 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 125 | 0.100 |
Why?
| | Aspergillosis | 1 | 2013 | 24 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2008 | 385 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 20 | 0.100 |
Why?
| | Child | 9 | 2022 | 22739 | 0.100 |
Why?
| | Telomerase | 3 | 2003 | 246 | 0.100 |
Why?
| | Cell Division | 5 | 2012 | 757 | 0.100 |
Why?
| | Seizures | 1 | 2017 | 485 | 0.090 |
Why?
| | Joint Dislocations | 1 | 1993 | 60 | 0.090 |
Why?
| | Spinal Injuries | 1 | 1993 | 60 | 0.090 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 246 | 0.090 |
Why?
| | Muscles | 1 | 1993 | 330 | 0.090 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 86 | 0.090 |
Why?
| | Patient Readmission | 1 | 2018 | 772 | 0.090 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1043 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 131 | 0.090 |
Why?
| | Craniotomy | 3 | 2015 | 84 | 0.090 |
Why?
| | Dog Diseases | 1 | 2013 | 106 | 0.090 |
Why?
| | Drug Resistance, Multiple | 2 | 2001 | 25 | 0.090 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 72 | 0.090 |
Why?
| | Spine | 1 | 1993 | 182 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 76 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1139 | 0.080 |
Why?
| | Curriculum | 1 | 2018 | 1074 | 0.080 |
Why?
| | Skull | 2 | 2007 | 163 | 0.080 |
Why?
| | Mitotic Index | 2 | 2011 | 25 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3551 | 0.080 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 6 | 0.080 |
Why?
| | Hyperthermia, Induced | 2 | 2002 | 120 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.080 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.080 |
Why?
| | Claudins | 1 | 2010 | 23 | 0.080 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 34 | 0.080 |
Why?
| | Tumor Burden | 4 | 2012 | 325 | 0.080 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.080 |
Why?
| | Tanzania | 2 | 2020 | 72 | 0.070 |
Why?
| | Immunity, Cellular | 2 | 2003 | 274 | 0.070 |
Why?
| | Animals | 14 | 2013 | 38097 | 0.070 |
Why?
| | Lymphoma | 2 | 2008 | 241 | 0.070 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.070 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 322 | 0.070 |
Why?
| | Piperidines | 1 | 2010 | 222 | 0.070 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.070 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 12 | 0.070 |
Why?
| | Cell Survival | 5 | 2015 | 1103 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 11 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2410 | 0.070 |
Why?
| | Genetic Vectors | 2 | 2008 | 335 | 0.070 |
Why?
| | Arm Injuries | 1 | 1988 | 25 | 0.070 |
Why?
| | Prolactin | 3 | 2019 | 87 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 224 | 0.070 |
Why?
| | Dogs | 2 | 2013 | 478 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 630 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 2 | 2025 | 26 | 0.070 |
Why?
| | Steroidogenic Factor 1 | 2 | 2025 | 13 | 0.070 |
Why?
| | Internship and Residency | 1 | 2018 | 1269 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 782 | 0.070 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 288 | 0.060 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 308 | 0.060 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 72 | 0.060 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.060 |
Why?
| | Mesenchymoma | 1 | 2007 | 9 | 0.060 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 101 | 0.060 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 19 | 0.060 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 13 | 0.060 |
Why?
| | Hematoma | 2 | 1985 | 63 | 0.060 |
Why?
| | Adenoviridae | 1 | 2008 | 199 | 0.060 |
Why?
| | Blood Vessels | 1 | 1988 | 167 | 0.060 |
Why?
| | Scalp | 1 | 2007 | 38 | 0.060 |
Why?
| | Radiography | 3 | 2013 | 853 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 47 | 0.060 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1474 | 0.060 |
Why?
| | Enophthalmos | 1 | 2006 | 4 | 0.060 |
Why?
| | Dexamethasone | 4 | 2012 | 365 | 0.060 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 10 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 489 | 0.060 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 14 | 0.060 |
Why?
| | Blepharoptosis | 1 | 2006 | 13 | 0.060 |
Why?
| | Epidermal Cyst | 1 | 2006 | 13 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2006 | 149 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 170 | 0.060 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 77 | 0.060 |
Why?
| | Parietal Lobe | 1 | 2006 | 61 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 1994 | 962 | 0.060 |
Why?
| | Vaccination | 2 | 2023 | 1428 | 0.060 |
Why?
| | Brain Edema | 2 | 2004 | 62 | 0.060 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 56 | 0.060 |
Why?
| | Child, Preschool | 5 | 2017 | 11868 | 0.060 |
Why?
| | Teratoma | 1 | 2007 | 124 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 457 | 0.060 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 37 | 0.060 |
Why?
| | Chest Pain | 1 | 2006 | 99 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 143 | 0.060 |
Why?
| | Bone Diseases | 1 | 2006 | 61 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 316 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 50 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 211 | 0.060 |
Why?
| | Benzamides | 1 | 2006 | 226 | 0.050 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 321 | 0.050 |
Why?
| | Exons | 1 | 2006 | 364 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 141 | 0.050 |
Why?
| | Cushing Syndrome | 1 | 2004 | 10 | 0.050 |
Why?
| | Antigens, CD | 2 | 2024 | 558 | 0.050 |
Why?
| | Calcitonin | 1 | 2004 | 27 | 0.050 |
Why?
| | Medulloblastoma | 1 | 2007 | 215 | 0.050 |
Why?
| | Databases, Factual | 1 | 2010 | 1491 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2006 | 4568 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2123 | 0.050 |
Why?
| | Subarachnoid Space | 1 | 2004 | 8 | 0.050 |
Why?
| | Myelography | 2 | 2022 | 44 | 0.050 |
Why?
| | Bevacizumab | 2 | 2015 | 168 | 0.050 |
Why?
| | S100 Proteins | 2 | 1995 | 35 | 0.050 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 12 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 979 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 14 | 0.050 |
Why?
| | Radiotherapy | 1 | 2004 | 206 | 0.050 |
Why?
| | United States | 3 | 2017 | 16123 | 0.050 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 20 | 0.050 |
Why?
| | Brain | 6 | 2017 | 2969 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 375 | 0.050 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1133 | 0.050 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 179 | 0.050 |
Why?
| | Proteomics | 2 | 2024 | 1188 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 592 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 485 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 200 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 3346 | 0.050 |
Why?
| | Dura Mater | 2 | 2000 | 40 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 442 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2865 | 0.050 |
Why?
| | Incidence | 3 | 2003 | 2933 | 0.050 |
Why?
| | Pyrimidines | 1 | 2006 | 530 | 0.050 |
Why?
| | Quality of Life | 2 | 2013 | 3210 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 298 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 27 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 194 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 474 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2021 | 3634 | 0.040 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 160 | 0.040 |
Why?
| | Thyrotropin | 5 | 1999 | 120 | 0.040 |
Why?
| | Public Opinion | 1 | 2021 | 62 | 0.040 |
Why?
| | Spinal Cord | 1 | 2004 | 382 | 0.040 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 70 | 0.040 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 67 | 0.040 |
Why?
| | Gene Amplification | 2 | 2015 | 118 | 0.040 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 6 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2003 | 883 | 0.040 |
Why?
| | Frontal Sinus | 1 | 2000 | 6 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2021 | 176 | 0.040 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 838 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 105 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 44 | 0.040 |
Why?
| | Visual Fields | 1 | 2020 | 116 | 0.040 |
Why?
| | Pituitary Hormones | 1 | 1999 | 15 | 0.040 |
Why?
| | Dopamine Agonists | 1 | 2019 | 41 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 329 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 852 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 17 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1139 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 474 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2443 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 848 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 35 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 381 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 396 | 0.040 |
Why?
| | Infant | 2 | 2008 | 10090 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 16 | 0.030 |
Why?
| | Biopsy | 2 | 2017 | 1082 | 0.030 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.030 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 20 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 96 | 0.030 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 29 | 0.030 |
Why?
| | Capacity Building | 1 | 2018 | 62 | 0.030 |
Why?
| | Meningomyelocele | 1 | 1998 | 62 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2018 | 85 | 0.030 |
Why?
| | Cell Line | 3 | 2012 | 2823 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 337 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 354 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 195 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 61 | 0.030 |
Why?
| | Hypophysitis | 1 | 2017 | 3 | 0.030 |
Why?
| | Brain Diseases | 2 | 1998 | 155 | 0.030 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 10 | 0.030 |
Why?
| | Preoperative Care | 2 | 2003 | 380 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2000 | 784 | 0.030 |
Why?
| | Hydrocephalus | 2 | 2017 | 111 | 0.030 |
Why?
| | Visual Acuity | 1 | 2020 | 490 | 0.030 |
Why?
| | Ventriculostomy | 1 | 2017 | 24 | 0.030 |
Why?
| | Neuroendoscopy | 1 | 2017 | 24 | 0.030 |
Why?
| | Premenopause | 1 | 2017 | 125 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 117 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 200 | 0.030 |
Why?
| | Gonadotropins | 2 | 1999 | 44 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 116 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 690 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 88 | 0.030 |
Why?
| | Granuloma | 1 | 2017 | 97 | 0.030 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 75 | 0.030 |
Why?
| | RNA, Messenger | 5 | 2011 | 2805 | 0.030 |
Why?
| | Postoperative Care | 1 | 1998 | 286 | 0.030 |
Why?
| | Immunophenotyping | 1 | 1997 | 322 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 189 | 0.030 |
Why?
| | Developing Countries | 1 | 2018 | 317 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 544 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 317 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 157 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| | Drainage | 1 | 2017 | 185 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 956 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1372 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 2 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 5223 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 337 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 295 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1437 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 669 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 4151 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 305 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 56 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 35 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 246 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 23 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 38 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 47 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 59 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4556 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 61 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 22 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 105 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 44 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 119 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1368 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 78 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1137 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 300 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 247 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 188 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 1003 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 782 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 264 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 189 | 0.020 |
Why?
| | SEER Program | 1 | 2014 | 230 | 0.020 |
Why?
| | Paresis | 2 | 2007 | 30 | 0.020 |
Why?
| | Cohort Studies | 2 | 2017 | 6032 | 0.020 |
Why?
| | Hypothyroidism | 2 | 1992 | 68 | 0.020 |
Why?
| | Nervous System | 1 | 1993 | 69 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1764 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 25 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 298 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1812 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 440 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 855 | 0.020 |
Why?
| | Safety | 1 | 1994 | 358 | 0.020 |
Why?
| | Fatal Outcome | 2 | 2007 | 305 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 194 | 0.020 |
Why?
| | Mice | 4 | 2012 | 18355 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2028 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 54 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 39 | 0.020 |
Why?
| | Neuroblastoma | 1 | 1993 | 174 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 1993 | 272 | 0.020 |
Why?
| | Lymphocytosis | 1 | 1992 | 12 | 0.020 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1505 | 0.020 |
Why?
| | Rhodamine 123 | 2 | 2001 | 8 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3416 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 117 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 376 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1300 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 171 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 443 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 16 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 254 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 55 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 39 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 407 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 165 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 716 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 227 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 63 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 508 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 80 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1850 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 164 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 144 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 138 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 156 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 411 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 179 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 244 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 165 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 93 | 0.020 |
Why?
| | Doxorubicin | 2 | 2001 | 403 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1568 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 788 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 21 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 34 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 13 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 266 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2110 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 95 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 28 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 437 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 478 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 112 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 849 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 867 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 35 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 6464 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 210 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 469 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3752 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 505 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1247 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 233 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 376 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1330 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1049 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 414 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 210 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2010 | 532 | 0.010 |
Why?
| | Pregnancy Complications | 1 | 1992 | 603 | 0.010 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 143 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2008 | 310 | 0.010 |
Why?
| | Tretinoin | 1 | 2006 | 125 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 426 | 0.010 |
Why?
| | Coma | 1 | 1985 | 38 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 368 | 0.010 |
Why?
| | Action Potentials | 1 | 1988 | 502 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1985 | 65 | 0.010 |
Why?
| | Athletic Injuries | 1 | 1991 | 573 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1271 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 981 | 0.010 |
Why?
| | Citrates | 1 | 1984 | 41 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 160 | 0.010 |
Why?
| | Sound | 1 | 1984 | 55 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2008 | 779 | 0.010 |
Why?
| | Brain Concussion | 1 | 1991 | 646 | 0.010 |
Why?
| | Blood | 1 | 1984 | 107 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 46 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2399 | 0.010 |
Why?
| | Injections | 1 | 1984 | 199 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 466 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 247 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 69 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 71 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 61 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 142 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1478 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 37 | 0.010 |
Why?
| | Ultrasonic Therapy | 1 | 2001 | 16 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 166 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 714 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 207 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 946 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4116 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2131 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2883 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 4 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 12 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 30 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 40 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 63 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 209 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 51 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 83 | 0.010 |
Why?
| | Photography | 1 | 1998 | 119 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 74 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 76 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 68 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 172 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 148 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 331 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 169 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 237 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 252 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 523 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5992 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 44 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 235 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 692 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 2000 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 107 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 19 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 22 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 24 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 47 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 168 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 63 | 0.010 |
Why?
| | Headache | 1 | 1992 | 151 | 0.010 |
Why?
| | Football | 1 | 1991 | 89 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 6085 | 0.000 |
Why?
| | Immunochemistry | 1 | 1989 | 12 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 66 | 0.000 |
Why?
| | Hyperthyroidism | 1 | 1989 | 22 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1989 | 78 | 0.000 |
Why?
| | Circadian Rhythm | 1 | 1991 | 513 | 0.000 |
Why?
| | Neutrophils | 1 | 1989 | 1125 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1454 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 69 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 34 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 33 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1997 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 3170 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2601 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 7215 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|